ClinicalTrials.Veeva

Menu

A Study of Pulmonary Hypertension Peripheral Limitations

Mayo Clinic logo

Mayo Clinic

Status

Enrolling

Conditions

Healthy
Pulmonary Arterial Hypertension

Treatments

Behavioral: Leg Training
Behavioral: Aerobic Training

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT05968859
23-000705
1K23HL164901-01A1 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The investigators are doing this research study to compare whole body aerobic training with isolated leg training (with weights) and its impact on effectiveness in symptoms and quality of life in patients with Pulmonary Arterial Hypertension (PAH).

Enrollment

45 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Pulmonary Arterial Hypertension (PAH) Subjects:

    1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
    2. NYHA Class II-IV
    3. LVEF ≥ 40 % within the preceding year.
    4. No hospitalizations due to heart failure in the preceding 30 days.
    5. No recent initiation of pulmonary vasodilator in the last 60 days
    6. Pulmonary arterial hypertension by right heart catheterization (Mean PA pressure ≥ 20 mmHg with PVR>2 Wood units) with no evidence of heart failure with preserved ejection fraction (exercise PCWP <25 mm Hg).
    7. Symptomatic PAH patients with plan to undergo exercise RHC for reassessment of exertional symptoms
  2. Healthy Controls:

    1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
    2. No known diagnosis of heart failure

Exclusion criteria

  • Myocardial infarction, stroke, hospitalization for heart failure, unstable angina pectoris or transient ischemic attack within 30 days prior to the day of screening.
  • Planned coronary, carotid, or peripheral artery revascularization.
  • Any other condition judged by the investigator to be the primary cause of dyspnea (such as heart failure due to restrictive cardiomyopathy or infiltrative conditions (e.g., amyloidosis), hypertrophic obstructive cardiomyopathy, anemia, or more than moderate mitral or aortic heart valve disease).
  • Wheelchair bound or orthopedic inability to exercise
  • Chronic hypoxemia with inability to exercise without oxygen supplementation (PAH Subjects) or need for oxygen supplementation (Healthy Controls)
  • Skeletal muscle myopathy
  • History of rhabdomyolysis
  • Participation in any clinical trial of an approved or non-approved device for the treatment of pulmonary hypertension within 30 days before screening.
  • Receipt of any investigational medicinal product within 30 days before screening
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
  • Major surgery scheduled for the duration of the trial, affecting walking ability in the opinion of the investigator.
  • Any disorder, including severe psychiatric disorder, suicidal behavior within 90 days before screening, and suspected drug abuse, which in the investigator´s opinion might jeopardize subject´s safety or compliance with the protocol.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

45 participants in 3 patient groups

Aerobic Training
Active Comparator group
Description:
Subjects with PAH will be enrolled to complete baseline study assessments, be randomized to undergo aerobic training for 12 weeks, and then repeat study assessments.
Treatment:
Behavioral: Aerobic Training
Leg Training
Experimental group
Description:
Subjects with PAH will be enrolled to complete baseline study assessments, be randomized to undergo leg training for 12 weeks, and then repeat study assessments.
Treatment:
Behavioral: Leg Training
Healthy Controls
No Intervention group
Description:
Healthy controls will be enrolled to complete the baseline study assessments for generation of normal reference values for comparison. Healthy controls will not undergo randomized exercise training interventions or repeat assessments.

Trial contacts and locations

1

Loading...

Central trial contact

Circulatory Failure Research Team; Yogesh Reddy

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems